Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
The purpose of this study is to determine the safety and efficacy of an experimental drug, abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) fixed dose combination as a single tablet regimen compared with subjects taking their current combined antiretroviral therapy (cART) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed
Who may be Eligible
Adults 18 or older; Agree not to become pregnant or father a child during the study term; Have an HIV viral load <50 for past 2 visits; Have been on current regimen for >6 months; Have stable maintenance labs; Not be on Dolutegravir (Tivicay) or Etravirine (Intelence); Normal EKG